In ovarian cancer, combination therapy with CXCL13 and an anti-PD-1 antibody inhibited tumor growth in a CXCR5+CD8+ T-cell expansion-dependent manner (23). This evidence concerns the gene CXCR5 and ovarian carcinoma.